查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1239519

叢集性頭痛市場：按類型、藥物類別和分銷渠道分類：2021-2031 年全球機遇分析和行業預測

Cluster Headache Market By Type, By Drug class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 233 Pages | 商品交期: 2-3個工作天內

價格

叢集性頭痛市場規模預計到 2021 年將達到 3.56 億美元，到 2031 年將達到 5.2298 億美元，2022 年至 2031 年的複合年增長率為 3.9%。

叢集性頭痛是最常見的原發性頭痛類型，稱為三叉神經自主神經痛 (TAC)。 叢集性頭痛的特徵是持續 15 至 180 分鐘的非常嚴重的單側頭痛發作，每天發作多達數次。 它的特點是疼痛的嚴重程度、發作的持續時間以及是否存在流淚和結膜充血等顱神經系統自主神經症狀。 發作通常成群發生，一次連續發生數周至數月，隨後是完全緩解期。 這種顯著的疼痛與自殺傾向增加有關，尤其是在集群期。

叢集性頭痛市場的驅動因素是叢集性頭痛患者人數的增加以及對開發叢集性頭痛有效療法的投資增加。 此外，叢集性頭痛等神經系統疾病發病率的急劇增加增加了對有效治療頭痛疾病的藥物的需求，叢集性頭痛發病率的增加有望推動市場增長。 例如，發表在 SAGE Journal-Cephalalgia 2022 上的一篇論文發現，挪威的叢集性頭痛患病率為每 10 萬人/年 48.6 例，推動了市場增長。 預計未來幾年將獲得監管機構批准的叢集性頭痛治療管道不斷增加，預計也將推動市場擴張。

此外，政府和私人組織還為與叢集性頭痛等頭痛疾病相關的研發活動提供各種補助金和獎學金，這進一步推動了市場擴張。 例如，根據國際頭痛學會（International Headache Society，IHS）2022 報告，IHS 支持年輕研究人員的創新和有影響力的研究，促進頭痛領域年輕研究人員的職業發展，並建立頭痛疾病知識庫。它提供了一個“IHS Junior Research Grant”等總共 20-30 項研究補助金將增加，這些可用於頭痛疾病研發的研究補助金有望推動市場增長。

然而，緩慢的藥物審批和嚴格的監管是製約市場增長的因素。 缺乏有利的報銷政策預計也將成為抑制市場增長的一個因素。

此外，對生物製劑等新型治療藥物的需求不斷增加，對治療方式的認識不斷提高，以及為開發安全有效的叢集性頭痛治療劑而加大研發力度，這些都是叢集性頭痛市場的主要因素。它提供了有利可圖的機會對於市場。

內容

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 主要投資領域
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 中等強度的競爭
  • 市場動態
    • 促進因素
      • 叢集性頭痛患病率上升
      • 開發治療叢集性頭痛的新型藥物
      • 對叢集性頭痛的認識不斷提高
    • 抑制因素
      • 用於叢集性頭痛的藥物的副作用
    • 機會
      • 新興市場的增長機會
  • 分析 COVID-19 對市場的影響

第 4 章叢集性頭痛市場：按類型

  • 概覽
    • 市場規模和預測
  • 反復發作
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 慢性
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章叢集性頭痛市場：按藥物類別分類

  • 概覽
    • 市場規模和預測
  • 麥角衍生物
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 鈣通道阻滯劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 曲普坦
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章叢集性頭痛市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 藥店和零售藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章叢集性頭痛市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按藥物類別劃分的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
  • 歐洲
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按藥物類別劃分的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
  • 亞太地區
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按藥物類別劃分的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 按藥物類別劃分的市場規模和預測
    • 按分銷渠道劃分的市場規模和預測
    • 市場規模和預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測
      • 其他拉丁美洲/中東/非洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 按藥物類別劃分的市場規模和預測
      • 按分銷渠道劃分的市場規模和預測

第 8 章競爭格局

  • 介紹
  • 關鍵成功策略
  • 排名前 10 位的玩家產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 2021 年最佳球員排名

第 9 章公司簡介

  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • FRESENIUS SE & Co. KGaA（Fresenius Kabi）
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Arrotex Australia Group
  • Grunenthal
Product Code: A14443

The cluster headache market size valued for $356.00 million in 2021 and is estimated to reach $522.98 million by 2031, exhibiting a CAGR of 3.9% from 2022 to 2031.  

Cluster headache is the most common type of the primary headache known as trigeminal autonomic cephalgia (TACs). Cluster headache is characterized by attacks of very severe, unilateral headache lasting 15-180 minutes, up to several times per day. It is distinguished by the severe nature of the pain, length of attacks, and presence of cranial autonomic symptoms such as lacrimation and conjunctival injection. Attacks often cluster and can occur in series for weeks or months at a time, followed by a period of complete remission. This significant pain is accompanied by increased suicidality during cluster periods, particularly during the time of the headache.   

The driving factors for cluster headache market are increase in number of patients suffering from cluster headache, and rise in investments for development of effective medications for cluster headache.  Moreover, surge in incidences of neurological disorders such as cluster headache results in demand of effective medications for treating headache disorders, thus increasing incidences of cluster headache is expected to drive the growth of the market. For instance, according to article published in SAGE Journal - Cephalalgia 2022, stated that, prevalence of cluster headache in Norway was found to be 48.6 per 100,000/year, thereby driving the growth of the market. In addition, increase in number of pipeline medications for treating cluster headache that is anticipated to receive regulatory approval in the upcoming years is projected to propel market expansion.     

Further, various grants and fellowships are provided by government and private institutions for research and development activities involving headache disorders such as cluster headache, which further propels the market expansion. For instance, according to report of International Headache Society (IHS) 2022, stated that, IHS offers total 20-30 fellowships such as 'IHS Junior Research Grant' to support innovative and impactful research from young investigators, promote the career of young investigators in the field of headache and increase the knowledge base of headache disorders, thus such available fellowships for R&D in headache disorders is anticipated to drive the growth of the market.    

However, lengthy drug approval process and strict regulatory pathways are the factors that restrain the growth of the market. In addition, absence of favorable reimbursement policies is also expected to constrain the growth of the market.   

Further, rise in demand for novel therapies such as biologics, increase in awareness about treatment options and increase in R&D to develop safe and efficacious drugs for cluster headache treatment offer lucrative opportunities to key players of the cluster headache market.  

The cluster headache market is segmented into type, drug class, distribution channel and region. By type, the market is categorized into episodic and chronic. By drug class, the market is categorized into ergot derivatives, calcium channel blockers, triptans, and others. By distribution channel, the market is categorized into hospital pharmacies, online providers and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  

Major Key players that operate in the global cluster headache market are Arrotex Australia Group, AstraZeneca, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.  

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cluster headache market analysis from 2021 to 2031 to identify the prevailing cluster headache market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cluster headache market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cluster headache market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug class

  • Ergot derivatives
  • Calcium channel blockers
  • Triptans
  • Others

By Distribution channel

  • Hospital pharmacies
  • Drug stores and retail pharmacies
  • Others

By Type

  • Episodic
  • Chronic

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Dr. Reddy's Laboratories Ltd.
  • FRESENIUS SE & Co. KGaA (Fresenius Kabi)
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Arrotex Australia Group
  • Grunenthal
  • Eli Lilly and Company
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of cluster headache
      • 3.4.1.2. Development of novel therapeutics for treatment of cluster headache
      • 3.4.1.3. Increase in awareness about cluster headache
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects associated with medications used for cluster headache
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CLUSTER HEADACHE MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Episodic
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: CLUSTER HEADACHE MARKET, BY DRUG CLASS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Ergot derivatives
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Calcium channel blockers
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Triptans
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug stores and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: CLUSTER HEADACHE MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Drug class
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Drug class
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Drug class
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Drug class
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Drug class
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Drug class
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Drug class
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Drug class
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Drug class
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Drug class
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Drug class
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Drug class
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Drug class
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Drug class
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Drug class
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Drug class
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Drug class
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Drug class
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Drug class
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Drug class
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Drug class
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Drug class
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Drug class
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Dr. Reddy's Laboratories Ltd.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Eli Lilly and Company
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. FRESENIUS SE & Co. KGaA (Fresenius Kabi)
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. GlaxoSmithKline plc
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Novartis AG
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Pfizer Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Teva Pharmaceutical Industries Ltd.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Arrotex Australia Group
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Key strategic moves and developments
  • 9.10. Grunenthal
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. CLUSTER HEADACHE MARKET FOR EPISODIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. CLUSTER HEADACHE MARKET FOR CHRONIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. GLOBAL CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. CLUSTER HEADACHE MARKET FOR ERGOT DERIVATIVES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. CLUSTER HEADACHE MARKET FOR CALCIUM CHANNEL BLOCKERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. CLUSTER HEADACHE MARKET FOR TRIPTANS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. CLUSTER HEADACHE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. CLUSTER HEADACHE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. CLUSTER HEADACHE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. CLUSTER HEADACHE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. CLUSTER HEADACHE MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. NORTH AMERICA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. U.S. CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. U.S. CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. U.S. CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. CANADA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. CANADA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. CANADA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. MEXICO CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. MEXICO CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. MEXICO CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. EUROPE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. EUROPE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. EUROPE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. EUROPE CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GERMANY CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. GERMANY CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. GERMANY CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. FRANCE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. FRANCE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. FRANCE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. UK CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. UK CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. UK CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. ITALY CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. ITALY CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. ITALY CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SPAIN CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SPAIN CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SPAIN CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF EUROPE CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. REST OF EUROPE CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF EUROPE CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. JAPAN CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. JAPAN CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. JAPAN CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CHINA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. CHINA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. CHINA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. INDIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. INDIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. INDIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. AUSTRALIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. AUSTRALIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. AUSTRALIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. SOUTH KOREA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. SOUTH KOREA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. SOUTH KOREA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. LAMEA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. LAMEA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. LAMEA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. LAMEA CLUSTER HEADACHE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. BRAZIL CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. BRAZIL CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. BRAZIL CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SAUDI ARABIA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH AFRICA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. REST OF LAMEA CLUSTER HEADACHE MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. REST OF LAMEA CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF LAMEA CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. DR. REDDY'S LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 88. DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 89. DR. REDDY'S LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 90. DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 91. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 92. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 93. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 94. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 95. ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 96. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): KEY EXECUTIVES
  • TABLE 97. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): COMPANY SNAPSHOT
  • TABLE 98. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT SEGMENTS
  • TABLE 99. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT PORTFOLIO
  • TABLE 100. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 101. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 102. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 103. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 104. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 105. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 106. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 107. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 108. PFIZER INC.: KEY EXECUTIVES
  • TABLE 109. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 110. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 111. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 115. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 120. ARROTEX AUSTRALIA GROUP: KEY EXECUTIVES
  • TABLE 121. ARROTEX AUSTRALIA GROUP: COMPANY SNAPSHOT
  • TABLE 122. ARROTEX AUSTRALIA GROUP: PRODUCT SEGMENTS
  • TABLE 123. ARROTEX AUSTRALIA GROUP: PRODUCT PORTFOLIO
  • TABLE 124. ARROTEX AUSTRALIA GROUP: KEY STRATERGIES
  • TABLE 125. GRUNENTHAL: KEY EXECUTIVES
  • TABLE 126. GRUNENTHAL: COMPANY SNAPSHOT
  • TABLE 127. GRUNENTHAL: PRODUCT SEGMENTS
  • TABLE 128. GRUNENTHAL: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. CLUSTER HEADACHE MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF CLUSTER HEADACHE MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN CLUSTER HEADACHE MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCLUSTER HEADACHE MARKET
  • FIGURE 10. CLUSTER HEADACHE MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR EPISODIC, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR CHRONIC, BY COUNTRY 2021-2031(%)
  • FIGURE 13. CLUSTER HEADACHE MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR ERGOT DERIVATIVES, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR CALCIUM CHANNEL BLOCKERS, BY COUNTRY 2021-2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR TRIPTANS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. CLUSTER HEADACHE MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CLUSTER HEADACHE MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 22. CLUSTER HEADACHE MARKET BY REGION, 2021
  • FIGURE 23. U.S. CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. INDIA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. AUSTRALIA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH AFRICA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA CLUSTER HEADACHE MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: CLUSTER HEADACHE MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. DR. REDDY'S LABORATORIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. ELI LILLY AND COMPANY: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 53. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 54. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 55. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 56. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 57. GLAXOSMITHKLINE PLC: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 58. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. NOVARTIS AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. NOVARTIS AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 65. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 66. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 69. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 70. GRUNENTHAL: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 71. GRUNENTHAL: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 72. GRUNENTHAL: REVENUE SHARE BY REGION, 2021 (%)